Skip to main content
Intermediate Technical IVT

residual disease

Remaining tumor tissue found at surgical resection after completion of neoadjuvant therapy, indicating incomplete response to treatment.

Full Definition

Residual disease refers to the presence of viable tumor cells in the breast and/or lymph nodes at the time of definitive surgery following neoadjuvant (preoperative) systemic therapy. The extent of residual disease is an important prognostic factor, with the absence of residual disease (pathological complete response) associated with improved long-term outcomes. Residual disease is quantified using various scoring systems, such as the residual cancer burden (RCB) classification, which incorporates tumor size, cellularity, and lymph node involvement. The assessment requires careful pathological examination to distinguish viable tumor cells from treatment-related changes such as fibrosis, inflammation, and necrosis. The presence and extent of residual disease influences decisions about additional adjuvant therapy and provides valuable prognostic information for patient counseling.

Usage

Usage note: In neoadjuvant context, distinguish from recurrent disease which occurs after a period of remission.

In Context

  • "Minimal residual disease was identified in the surgical specimen after neoadjuvant chemotherapy." — Pathology report
  • "The extent of residual disease determined the need for additional adjuvant therapy." — Treatment planning discussion

Also known as

residual tumor residual cancer burden

Contrasted with

pathological complete response

Don't confuse with

minimal residual disease recurrent disease progressive disease

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON